Portage Biotech Files 6-K, Incorporates into S-8
Ticker: ATON · Form: 6-K · Filed: Oct 4, 2024 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, registration, foreign-issuer
TL;DR
Portage Biotech filed a 6-K, linking it to their S-8 registration. Standard reporting.
AI Summary
Portage Biotech Inc. filed a Form 6-K on October 4, 2024, to report information for the month of October 2024. The filing is incorporated by reference into the company's Form S-8 registration statement (File No. 333-275842). The company is registered in the British Virgin Islands and its principal executive offices are located in Tortola.
Why It Matters
This filing indicates ongoing reporting requirements and potential future stock issuances or grants related to employee compensation or other equity-based plans.
Risk Assessment
Risk Level: low — This is a routine filing for a public company and does not contain specific financial or operational news that would immediately impact risk.
Key Numbers
- 001-40086 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- Portage Biotech Inc. (company) — Filer of the 6-K report
- 333-275842 (dollar_amount) — File number for the Form S-8 registration statement
- October 4, 2024 (date) — Filing date of the Form 6-K
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have distributed or are required to distribute to their security holders.
What is Form S-8 used for?
Form S-8 is used by companies to register securities that will be offered to employees under an employee benefit plan.
Where is Portage Biotech Inc. incorporated?
Portage Biotech Inc. is incorporated in the British Virgin Islands.
What is the SIC code for Portage Biotech Inc.?
The Standard Industrial Classification (SIC) code for Portage Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was Portage Biotech Inc. formerly known as Bontan Corp Inc?
Portage Biotech Inc. was formerly known as Bontan Corp Inc. with a date of name change on April 21, 2003.
Filing Stats: 258 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-10-04 16:15:31
Filing Documents
- f6k_100424.htm (6-K) — 8KB
- 0001171843-24-005512.txt ( ) — 9KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant’s name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Management Changes On September 30, 2024, Allan Shaw, Chief Financial Officer of Portage Biotech Inc. (the “Company”), and Joseph Ciavarella, accounting consultant to the Company, departed from the Company. On September 30, 2024, Andrea Park, as Chief Financial Officer, and Adam Melero, as Controller, joined the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 4, 2024 PORTAGE BIOTECH INC. By: /s/ Andrea Park Andrea Park Chief Financial Officer